Browsing Tag
diagnostics
12 posts
What Alamar Biosciences’ (NASDAQ: ALMR) IPO pop says about the next phase of proteomics investing
Alamar Biosciences surged after its upsized IPO. Read what the debut means for proteomics, public markets, and life science tools investors.
Why Hims & Hers Health’s decision to offer Grail’s Galleri test looks riskier after the U.K. NHS trial miss
Grail’s Galleri cancer test missed a major U.K. NHS trial goal just as Hims & Hers Health began offering it. Find out what this means for investors and screening strategy.
GRAIL (Nasdaq: GRAL) files FDA application for Galleri test, aiming to redefine how cancer is detected in asymptomatic patients
GRAIL files FDA approval for Galleri, its blood-based test for early cancer detection. Find out what it means for diagnostics, payers, and public health.
Why U.S. based Trividia Health is gaining traction in blood glucose testing with TRUE METRIX
Trividia Health’s TRUE METRIX devices join Express Scripts’ preferred formulary. Discover how this U.S.-made glucose monitor is changing diabetes care access.
Guardant Health (NASDAQ: GH) surges 27% after blowout quarter: What it means for diagnostics investors
Find out how Guardant Health’s strong Q3 performance triggered a diagnostics rally — and what it means for investors in the early-detection boom.
Inside Thermo Fisher Scientific’s plan to harness OpenAI for faster, smarter biotech innovation
Find out how Thermo Fisher Scientific plans to use OpenAI’s generative AI to revolutionize research speed, accuracy, and discovery across life sciences.
Bluejay Diagnostics and SanyoSeiko deepen alliance to accelerate commercial launch of Symphony platform
Find out how Bluejay Diagnostics is accelerating Symphony’s commercial launch through an expanded SanyoSeiko partnership in manufacturing and supply chain.
Anbio Biotechnology responds to global outbreaks with chikungunya rapid test and 15-minute ultra-fast PCR system
Anbio Biotechnology (NASDAQ: NNNN) launches chikungunya rapid test and 15‑minute PCR, boosting its IVD leadership and investor interest in diagnostic innovation.
Suraksha Diagnostic Q1 FY26 results: How revenue growth, genomics expansion, and acquisitions are shaping investor outlook
Suraksha Diagnostic Q1 FY26 revenue up 18.83%, PAT up 19.67%. See how genomics, acquisitions, and expansion are shaping its growth outlook.
Gadoquatrane heads to FDA: Can Bayer lead the next generation of low-dose MRI contrast agents?
Bayer targets FDA nod for gadoquatrane, the lowest‑dose macrocyclic MRI contrast agent, potentially reshaping radiology practices globally.